Acromegaly is a chronic, slowly developing disease with progressive disfigurement and disability. An early diagnosis is difficult as most signs and symptoms are due to long-standing overproduction of growth hormone &/or insulin-like growth factor (IGF-I) causing metabolic, endocrine and morphological changes.
Surgical intervention is the first-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure.
The risk of incident vertebral fractures (VFs) is lower among acromegaly patients with biochemically active disease treated with pasireotide LAR (Pasi) compared with those on pegvisomant (PegV), reports a recent study, which also confirms that the presence of pre-existent VFs is the main cause of incident VFs.
Combined treatment with pasireotide and pegvisomant has been shown to control disease in tumours with low somatostatin receptor (SSTR) subtype 2 expression, resistant to conventional somatostatin analogues (SSAs; alone or combined with pegvisomant) and to new-generation SSAs alone (pasireotide), reports a recent study.
Treatment with somatostatin analogues (SSAs) improves disease control in patients with acromegaly but reduces insulin levels, increases after-load glucose and increases glycated haemoglobin (HbA1c) levels without affecting fasting plasma glucose (FPG), suggests a recent study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Endocrinology - Malaysia digital copy today!
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.